Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
Verapamil inhibits MRP-L39 by blocking its transport function, reducing the efflux of various substrates from cells. It does this by binding to calcium channels, indirectly affecting MRP-L39 activity. | ||||||
Probenecid | 57-66-9 | sc-202773 sc-202773A sc-202773B sc-202773C | 1 g 5 g 25 g 100 g | $28.00 $39.00 $100.00 $277.00 | 28 | |
Probenecid inhibits MRP-L39 by competing with its substrates for binding, thereby reducing the efflux of drugs and toxins from cells. It acts as a competitive inhibitor of MRP-L39 transport. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $138.00 $380.00 | 101 | |
Cisplatin induces cross-linking of DNA, leading to cell damage and apoptosis. This indirectly inhibits MRP-L39 by inhibiting the efflux of DNA-damaging agents. | ||||||
Quinidine | 56-54-2 | sc-212614 | 10 g | $104.00 | 3 | |
Quinidine inhibits MRP-L39 by affecting its ATPase activity, reducing energy supply for drug efflux. It also interferes with MRP-L39 substrate binding. | ||||||
(±)-Sulfinpyrazone | 57-96-5 | sc-202822 sc-202822A | 1 g 5 g | $42.00 $94.00 | 2 | |
Sulfinpyrazone inhibits MRP-L39 by competing with substrates for transport, reducing the efflux of drugs and xenobiotics. It acts as a competitive inhibitor. | ||||||
Indomethacin | 53-86-1 | sc-200503 sc-200503A | 1 g 5 g | $29.00 $38.00 | 18 | |
Indomethacin inhibits MRP-L39 by interfering with its ATPase activity, reducing the energy required for drug efflux. It also affects substrate binding. | ||||||
MK-571 | 115103-85-0 | sc-201340 sc-201340A | 5 mg 25 mg | $109.00 $421.00 | 8 | |
MK-571 inhibits MRP-L39 by binding to a specific site on the transporter, blocking the efflux of leukotrienes and other substrates. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $59.00 $173.00 | 15 | |
Nifedipine inhibits MRP-L39 by affecting its ATPase activity, reducing energy supply for drug efflux. It also interferes with MRP-L39 substrate binding. | ||||||
Diclofenac acid | 15307-86-5 | sc-357332 sc-357332A | 5 g 25 g | $109.00 $298.00 | 5 | |
Diclofenac acid inhibits MRP-L39 by interfering with its ATPase activity and substrate binding, reducing the efflux of various drugs and compounds. | ||||||
Furosemide | 54-31-9 | sc-203961 | 50 mg | $41.00 | ||
Furosemide inhibits MRP-L39 by competing with substrates for transport, reducing the efflux of drugs and xenobiotics. It acts as a competitive inhibitor. | ||||||